Table 1 Clinicopathological features of 280 patients with primary GIST that classified as medium and high risk
Characteristics | Before matching (n = 280) | After matching (n = 200) | ||||
|---|---|---|---|---|---|---|
TKIs-used group(n = 178) | TKIs-unused group(n = 102) | P value | TKIs-used group(n = 100) | TKIs-unused group(n = 100) | P value | |
Gender | 0.446 | 0.257 | ||||
Male(%) | 100(56.2) | 43(42.2) | 52(52.00) | 43(43.00) | ||
Female(%) | 78(43.8) | 59(57.8) | 48(48.00) | 57(57.00) | ||
Age (years) | 0.064 | |||||
≤ 60 years(%) | 116(65.2) | 50(49.0) | 52(52.00) | 50(50.00) | ||
> 60 years(%) | 62(34.8) | 52(51.0) | 48(48.00) | 50(50.00) | ||
Clinical manifestation | 0.469 | 0.362 | ||||
Abdominal discomfort or pain(%) | 41(23.03) | 24(23.53) | 36(36.00) | 39(39.0) | ||
Gastrointestinal bleeding(%) | 36(20.22) | 20(19.61) | 17(17.00) | 19(19.00) | ||
Obstruction(%) | 11(6.18) | 6(5.88) | 2(2.00) | 2(2.00) | ||
Perforation or rupture(%) | 14(7.87) | 10(9.80) | 8(8.00) | 9(9.00) | ||
Medical examination reported(%) | 68(38.20) | 36(35.29) | 32(32.00) | 27(27.00) | ||
Others(%) | 8(4.49) | 6(5.88) | 5(5.00) | 4(4.00) | ||
Preoperative laboratory variables | ||||||
Hemoglobin (g/L, \(\overline{x} \pm {\text{s}}\)) | 113.3 ± 22.3 | 108.5 ± 26.4 | 0.206 | 116.3 ± 25.6 | 108.3 ± 26.5 | |
White blood cell (109/L, \(\overline{x} \pm {\text{s}}\)) | 6.4 ± 2.5 | 6.7 ± 4.2 | 0.662 | 6.4 ± 2.5 | 6.7 ± 4.2 | |
Neutrophil count (109/L, \(\overline{x} \pm {\text{s}}\)) | 4.4 ± 3.2 | 4.5 ± 4.0 | 0.809 | 4.2 ± 2.3 | 4.6 ± 4.0 | |
Lymphocyte count (109/L, \(\overline{x} \pm {\text{s}}\)) | 1.5 ± 0.6 | 1.6 ± 1.4 | 0.397 | 1.6 ± 0.6 | 1.6 ± 1.4 | |
Platelet count (109/L, \(\overline{x} \pm {\text{s}}\)) | 230.4 ± 87.7 | 237.8 ± 103.3 | 0.616 | 226.6 ± 78.4 | 237.4 ± 104.4 | |
Albumin (g/L,\(\overline{x} \pm {\text{s}}\) | 38.9 ± 4.3 | 38.9 ± 4.8 | 0.992 | 39.0 ± 4.0 | 38.9 ± 4.9 | |
NLR (\(\overline{x} \pm {\text{s}}\)) | 4.0 ± 5.5 | 3.9 ± 5.1 | 0.939 | 3.5 ± 3.8 | 3.9 ± 5.1 | |
PLR (\(\overline{x} \pm {\text{s}}\)) | 182.7 ± 136.1 | 194.2 ± 143.3 | 0.339 | 170.3 ± 121.6 | 193.9 ± 143.9 | |
OPNI (\(\overline{x} \pm {\text{s}}\)) | 46.4 ± 5.7 | 46.4 ± 8.6 | 0.015 | 47.2 ± 5.7 | 46.4 ± 8.6 | |
Primary tumor site | < 0.001 | 0.137 | ||||
Stomach(%) | 114(64.04) | 68(66.67) | 75(75.00) | 66(66.00) | ||
Small intestine(%) | 54(30.34) | 30(29.41) | 20(20.00) | 30(30.00) | ||
Colorectum(%) | 3(1.69) | 2(1.96) | 2(2.00) | 2(2.00) | ||
Intraperitoneally with unknown origin(%) | 7(3.93) | 2(1.96) | 3(3.00) | 2(2.00) | ||
Tumor size (cm,\(\overline{\user2{x}}{\mathbf{ \pm s}}\)) | 7.75 ± 3.64 | 7.17 ± 4.45 | 0.051 | 6.67 ± 2.75 | 7.16 ± 4.49 | 0.469 |
≤ 5.0(%) | 32(17.98) | 27(26.47) | 23(23.00) | 26(26.00) | ||
5.1–10.0(%) | 112(62.92) | 62(60.78) | 72(72.00) | 61(61.00) | ||
> 10.0(%) | 34(19.10) | 13(12.75) | 5(5.00) | 13(13.00) | ||
Predominant cell type | 0.685 | 0.795 | ||||
Spindle(%) | 170(19.50) | 92(90.30) | 95(95.00) | 90(90.00) | ||
Epithelioid(%) | 5(2.81) | 7(6.86) | 4(4.00) | 7(7.00) | ||
Mixed (%) | 3(1.69) | 3(2.94) | 1(1.00) | 3(3.00) | ||
Mitotic index (per 50 HPFs) | 0.875 | 0.250 | ||||
≤ 5(%) | 85(47.75) | 47(46.08) | 53(53.00) | 45(45.00) | ||
6–10(%) | 35(19.66) | 26(25.49) | 21(21.00) | 26(26.00) | ||
> 10(%) | 58(32.58) | 29(28.43) | 26(26.00) | 29(29.00) | ||
Necrosis | 0.014 | 0.002 | ||||
Yes (%) | 62(34.83) | 32(31.37) | 33(33.00) | 37(37.00) | ||
No (%) | 116(65.17) | 70(68.63) | 67(67.00) | 63(63.00) | ||
Tumor rupture | < 0.001 | < 0.001 | ||||
Yes (%) | 23(12.92) | 14(13.73) | 6(6.00) | 7(7.00) | ||
No (%) | 155(87.08) | 88(86.27) | 94(94.00) | 93(93.00) | ||
Risk classification | 0.096 | 0.024 | ||||
Intermediate(%) risk | 59(33.15) | 44(43.14) | 58(58.00) | 42(42.00) | ||
High risk(%) | 119(66.85) | 58(56.86) | 42(42.00) | 58(58.00) | ||
CD117 | 0.279 | 0.031 | ||||
(–) (%) | 3(1.69) | 5(4.90) | 2(2.00) | 5(5.00) | ||
( +)(%) | 37(20.79) | 27(26.47) | 23(23.00) | 25(25.00) | ||
(+ +)(%) | 35(19.66) | 10(9.80) | 17(17.00) | 11(11.00) | ||
(+ + +)(%) | 103(57.87) | 60(58.82) | 58(58.00) | 59(59.00) | ||
CD34 | 0.257 | 0.531 | ||||
(–) (%) | 20(11.24) | 12(11.76) | 10(10.00) | 12(12.00) | ||
( +)(%) | 33(18.54) | 36(35.29) | 15(15.00) | 33(33.00) | ||
(+ +)(%) | 22(12.36) | 8(7.84) | 12(12.00) | 8(8.00) | ||
(+ + +)(%) | 103(57.87) | 46(45.10) | 63(63.00) | 46(46.00) | ||
Ki-67 index (%,\(\overline{\user2{x}}{\mathbf{ \pm s}}\)) | 7.87 ± 7.66 | 7.31 ± 7.59 | 0.019 | 7.01 ± 6.62 | 7.35 ± 7.69 | 0.766 |
≤ 5(%) | 110(61.80) | 64(62.75) | 67(67.00) | 63(63.00) | ||
6–10(%) | 35(19.66) | 25(24.51) | 16(16.00) | 24(24.00) | ||
> 10(%) | 33(18.54) | 13(12.75) | 17(17.00) | 13(13.00) | ||
Follow-up time (months, \(\overline{x} \pm {\text{s}}\)) | 44.47 ± 25.07 | 55.01 ± 29.39 | 0.003 | 48.57 ± 24.61 | 53.98 ± 28.75 | < 0.001 |
Follow-up status | < 0.001 | < 0.001 | ||||
No relapse (%) | 146(82.02) | 72(70.59) | 85(85.00) | 70(70.00) | ||
Relapse (%) | 32(17.98) | 30(29.41) | 15(15.00) | 30(30.00) | ||